Piramal Pharma Limited announced its audited consolidated financial results for the quarter and year ended March 31, 2026, following a Board Meeting held on April 28, 2026. For the quarter ended March 31, 2026 (Q4FY26), the company reported a consolidated revenue from operations of ₹2,752 Crores, which remained nearly flat compared to ₹2,754 Crores in the corresponding quarter of the previous year (Q4FY25) and grew by 29% from ₹2,140 Crores in the preceding quarter (Q3FY26). The company recorded a consolidated Net Profit of ₹55 Crores in Q4FY26, reflecting a significant recovery from a loss of ₹18 Crores in Q3FY26, though it decreased from ₹101 Crores in Q4FY25. For the full fiscal year 2026, the company reported a consolidated net loss of ₹325.94 Crores against a total income of ₹9,082.38 Crores.

Piramal Pharma Limited (PPL) is a leading global pharmaceutical company with a diverse portfolio of products and services across three main business segments: Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG), and India Consumer Healthcare (PCH). The company offers end-to-end drug development and manufacturing solutions and maintains a strong presence in the inhalation anesthesia market, holding a 47% global market share in Sevoflurane as of 2026. In 2025, PPL focused on expanding its high-growth innovation-related work within the CDMO segment and strengthened its consumer health portfolio with brands like Lacto Calamine and Little’s. Notable corporate developments in 2025 included the acquisition of the Kenalog® brand to broaden its CHG portfolio and the formalization of a partnership with IntoCell to expand its bioconjugate capabilities. The company is backed by prominent institutional investors, including The Carlyle Group, which held approximately 17.97% stake as of late 2025.